An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment.
This is a video synopsis/summary of an Insights involving Eric D. Donnenfeld, MD.
Demodex blepharitis is the leading reason that patients visit eye physicians, making up 40% to 50% of eye care professional appointments. Many patients are misdiagnosed and mistreated for aqueous-deficient dry eye with expensive immunomodulators instead of given the correct Demodex blepharitis diagnosis. Correct diagnosis and treatment with Xdemvy(lotilaner ophthalmic solution) significantly cuts costs.
Once diagnosed, Demodex blepharitis responds well to treatment. Lotilaner is a safe and effective 6-week, twice-daily course that improves ocular surface disease for at least 1 year, showing long-term stability for this previously unmanaged chronic condition.
It is important that patients understand Demodex pathogenesis because an eyelash mite infestation, in addition to clinical outcomes, usually motivates treatment adherence.
Video synopsis is AIgenerated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More